Press release – For immediate release – 5:45 pm CET
Half year Median Technologies liquidity contract statement
Under the liquidity contract entrusted by Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, “Median” or “the Company”) to TP ICAP (Europe), the following resources were listed in the liquidity account as of December 31, 2025:
- 37,758 shares
- €166,854.84 in cash.
Transactions during the second half of 2025:
| BUY | 363,473 shares | 991,855.31 EUR | 582 transactions |
| SALE | 386,523 shares | 1,101,296.51 EUR | 506 transactions |
For information, as of June 30, 2025, the following resources were listed in the liquidity contract:
- 60,808 shares
- €58,893.66 in cash
For information, as of May 4th, 2020, when the new liquidity contract was set up, the following resources were listed in the liquidity account:
- 4,404 shares
- €173,829.64 in cash
The daily transaction table is provided in the appendix to this press release (pdf version). TP ICAP (Europe) is authorized and regulated by the Autorité de Contrôle Prudentiel (ACPR) and the Autorité des Marchés Financiers (AMF).
Pioneering innovative imaging services and Software as a Medical Device, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median’s offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit